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Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease in 
terms of survival outcomes. Moreover, multimodality treatment often leads to significant 
morbidity. As such, there is an urgent need for personalized prognostication and 
treatment strategies. It has been hypothesized that germline variations may account for 
some of the heterogeneity observed in individual survival outcomes as they may 
influence tumor progression and treatment response. The objective of this study was to 
utilize a genome-wide approach to examine the association between germline variants 
and overall survival in HNSCC. Whole blood samples from 1145 patients with newly 
diagnosed primary HNSCC (oral cavity, oropharynx, and hypopharynx) were collected. 
A custom-designed Illumina Oncoarray BeadChip was used to interrogate 533,631 single 
nucleotide polymorphisms (SNPs) across the genome. After quality control measures, 
survival analysis using multivariate cox proportional hazards models was conducted on 
768 individuals of European descent. No variant reached the genome-wide threshold for 
significance. However, two loci’ associations with overall survival were suggestive of 
significance (p values < 1x10-6). Under the recessive model, rs1974051 located at 6p12.3 
was associated with decreased survival (HR, 2.09; 95% CI, 1.57-2.79). The other two 
significant SNPs were in high linkage disequilibrium (rs10812227 and rs12237653) with 
one another and were protective variants located at 9p24.2 (HR, 0.32; 95% CI, 0.20-0.50 
for each). Exploratory sensitivity analyses based on anatomical sub-site revealed two 
SNPs that reached genome-wide significance within the oral cavity (rs7862541) and 
oropharynx (rs7862541), suggesting that certain molecular pathways may be more 
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important in determining prognosis in one anatomical sub-site compared to another. In 
conclusion, this study identified novel germline variants located within loci known to be 
altered in HNSCC that may influence prognosis in European patients. Given their ease of 
detection, germline variants are ideal biomarkers for use in clinical settings. Further 
functional and validation studies are needed in order to determine the contribution, if any, 
of these candidate variants to prognostication in all or a subset of HNSCC patients.  
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1.1 Epidemiology  
 
Head and neck cancer is a broad term encompassing a variety of different 
malignancies occurring within regions of the head and neck including the mouth, nose, 
para-nasal sinuses, pharynx, skin, or cervical lymph nodes. Amongst primary head and 
neck cancers, squamous cell carcinoma (SCC) represents the predominant histologic 
tumor type accounting for over 90% of the cases (Suh, Amelio, Guerrero Urbano, & 
Tavassoli, 2014). With approximately 650,000 newly diagnosed cases and 350,000 
deaths each year, head and neck squamous cell carcinoma (HNSCC) carries a significant 
burden worldwide (Ferlay et al., 2010).  In the United States, there are over 50,000 new 
cases and 11,000 deaths annually (Jemal, Bray, & Ferlay, 2011). 
HNSCC arises from the epithelial lining of the upper aerodigestive tract and can 
be subcategorized by the involved anatomical sub-site(s). These include the oral cavity, 
nasopharynx, oropharynx, larynx, and the hypopharynx. Although there exists 
geographical variations in incidence and mortality for each anatomical sub-site, the oral 
cavity and oropharynx are the most common sites of disease overall worldwide (Argiris, 
Karamouzis, Raben, & Ferris, 2008).  
HNSCC typically develops in the 6th decade of life. There is largely a male 
predominance, but the male to female ratio varies from 2:1 to 15:1 depending on 
anatomical sub-site (Mehanna, Paleri, West, & Nutting, 2010). In general, there has been 
a trend towards stabilization or decreasing incidence for HNSCC as a whole due to 
declines in tobacco use (Simard, Torre, & Jemal, 2014). In contrast, an increase in the  
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global incidence of oropharyngeal cancer has been observed in recent years, particularly 
in younger age groups (40-50 years old) (Chaturvedi et al., 2013). 
Tobacco use and alcohol consumption are the predominant risk factors in 
approximately 75% of HNSCC cases (Hashibe et al., 2009). The risk associated with 
tobacco smoking directly correlates with intensity and duration of use. Smoking cessation 
reduces HNSCC risk, but does not lower it to levels of the never-smoker (Schlect, 
Franco, Pintos, & Kowalski, 1999). Heavy alcohol consumption is an independent risk 
factor that exerts a synergistic effect when combined with smoking (Hashibe et al., 2009).  
Along with the increase in oropharyngeal carcinoma incidence observed in recent 
years, the human papillomavirus (HPV) has also emerged as a major etiologic factor in 
this anatomical sub-site of HNSCCs. HPV infection has been associated with up to 80% 
of oropharyngeal cancers in the United States, with HPV subtypes 16 and 18 being 
responsible for the majority of cases (Marur, D’Souza, Westra, & Forastiere, 2010). In 
other anatomical sub-sites, HPV positivity is much lower. Depending on the method of 
detection, HPV positivity is associated with less than 10% of oral cavity, laryngeal, and 
hypopharyngeal tumors (Combes & Franceschi, 2014). Individuals with HPV-positive 
oropharyngeal carcinoma more often lack the classical risk factors of tobacco and alcohol 
consumption and have younger ages of disease onset compared to classical HNSCC 
(Marur, D’Souza, Westra, & Forastiere, 2010).  
1.2 Diagnosis and Treatment 
Patients with HNSCC present with various signs and symptoms related to the 
location of the primary tumor and involved structures. These may include pain, mucosal 
ulceration, odynophagia, dysphagia, dysphonia, hoarseness, otalgia, and neck mass. In 
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more advanced stages, HNSCC may present with cranial nerve palsies, airway 
obstruction, and constitutional symptoms including weight loss and fatigue. Biopsy is 
required for diagnosis. Accurate staging is paramount in guiding therapeutic decision 
making and involves complete physical examination, endoscopy, and imaging (X-ray, 
CT, MRI). The seventh edition of the American Joint Committee on Cancer (AJCC) 
TNM staging system is widely used currently and categorizes disease based on size of the 
primary tumor, invasion of adjacent structures, cervical lymph node involvement, and 
distant metastatic spread (Edge & Compton, 2010). Treatment regimen is anatomical sub-
site specific and usually involves multiple modalities except in the cases of very early 
disease. In North America, primary treatment typically consists of either surgical 
resection or radiotherapy. Adjuvant treatment using a second and/or third modality (i.e. 
chemotherapy, targeted therapy) is added depending on the extent of disease, patient’s 
age, medical comorbidities, and/or performance status (Argiris et al., 2008).  
1.3 Prognosis 
Based on Surveillance Epidemiology and End Results (SEER) data, the 5-year 
survival rate for all sub-sites and stages combined is approximately 65.9% (Pulte & 
Brenner, 2010). Pathologically confirmed cervical metastases upstages disease to stage 
III and significantly reduce survival rates by up to 50% (Layland, Sessions, & Lenox, 
2005). Distant metastases are late events that represent incurable disease. When detected 
early and managed in a timely and effective manner, early-staged HNSCC in some 
anatomical sub-sites may carry a favorable prognosis. The 5-year survival rates based on 
SEER data is greater than 80% for localized oral cavity and oropharynx carcinoma and 
approximately 75% for localized laryngeal and nasopharyngeal carcinomas (National 
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Cancer Institute, 2013; Ou, Zell, Ziogas, & Anton-Culver, 2007). Localized 
hypopharyngeal carcinoma is associated with the lowest survival rates of less than 60% 
(Siegel, Ma, Zou, & Jemal, 2014). 
HPV positive oropharyngeal carcinoma represents a distinct subgroup of HNSCC 
in terms of prognosis. Compared to traditional HNSCC associated with smoking and 
alcohol consumption, HPV-positive oropharyngeal carcinomas are associated with better 
survival rates and lower risks of recurrence. In this subgroup of patients, significant 
smoking history negatively impacts prognosis (Ang et al., 2010).  
In general, prognostication based on patient and clinical characteristics have 
proven insufficient alone. Given that individuals with similar disease characteristics and 
treatments strategies often have variable outcomes, it has become increasingly evident 
that HNSCC is a complex disease characterized by clinical and biological heterogeneity. 
Individual genetic variations may underlie this observed heterogeneity (Pai & Westra, 
2009). Moreover, for the substantial number of patients presenting with advanced 
disease, intensive multimodality treatment can cause significant functional impairments 
(Argiris et al., 2008). As such, there exists a need to identify biomarkers that can 
strengthen our understanding of the genetic underpinnings of HNSCC and improve our 
ability to predict outcomes and select patients for individualized therapeutic strategies.  
2. Literature Review 
2.1 Genetics of HNSCC 
The majority of HNSCC occur as sporadic cases. However, inheritable genetic 
risk factors appear to also play a role. Familial clustering were initially reported in oral 
and laryngeal cancers, suggesting a genetic component to the disease (Bhaskar, Smith, & 
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Baughman, 1988; Gencik, Wey, & Muller, 1986; Hara, Ozeki, Shiratsuchi, Tashiro, & 
Jingu, 1988; Marlowe, 1970). In family- and population-based case-control studies, 
history of HNSCC in a first-degree relative was associated with a 2-4 fold elevated risk 
of HNSCC (Copper et al., 1995; Foulkes et al., 1996; Foulkes, Brunet, Kowalski, Narod, 
& Franco, 1995; Radoï et al., 2013). The impact of genetic predisposition on HNSCC 
development is further demonstrated in rare cancer susceptibility syndromes including 
Fanconi’s anemia, xeroderma pigmentosum, Li-Fraumeni syndrome, Lynch syndrome, 
Blooms syndrome, and ataxia-telangiectasia, where incidence of HNSCC is markedly 
elevated even in the absence of environmental risk factors such as smoking and alcohol 
consumption (Trizna & Schantz, 1992). 
In attempts to identify specific genomic alterations associated with HNSCC, there 
has been a myriad of studies investigating somatic mutations in HNSCC tumors. From 
next-generation sequencing studies we have learned that the mutational landscape in 
HNSCC is diverse with aberrations in genes from a variety of cellular pathways (Agrawal 
et al., 2011; Lui et al., 2013; Stransky et al., 2011). While mutations in TP53, CDKN2A, 
NOTCH1, PIK3CA, and HRAS are the most common, data from The Cancer Genome 
Atlas (TCGA) has also revealed other novel alterations in the receptor tyrosine kinase 
family, cell death pathway, NF-kB-mediated survival pathway, and immunity pathway 
genes (The Cancer Genome Atlas Network, 2015). 
2.2 Germline Variations and HNSCC  
In comparison to somatic variations that are acquired as tumors develop, germline 
variations are heritable and non-tissue specific. In the setting of translational research, 
germline variations can provide an advantage over somatic variations given that they can 
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be easily detected from sources such as blood or saliva and do not change depending on 
intra-tumor heterogeneity.  
In the past decade, completion of the Human Genome Project and the 
International HapMap Project coupled with advances in high-throughput technologies 
have given rise to genome-wide association studies (GWAS) (The International Human 
Genome Sequencing Consortium, 2002; The International HapMap Consortium, 2003). 
These studies were traditionally routed in the Common Disease Common Variant 
Hypothesis (CVCD), which suggests that susceptibility to common diseases results from 
common genetic variations (minor allele frequency greater than 1-5%) found in the 
population of interest (Risch & Merikangas, 1996). These common genetic variations are 
captured in GWAS in the form of single nucleotide polymorphisms (SNPs), which are 
inheritable DNA sequence variations of a single base pair. GWAS relies on the principal 
of linkage disequilibrium (LD), where alleles at two or more genetic loci are non-
randomly associated within a population. Because of LD, it is possible to study the 
associations of genetic variations with phenotypes of interest on a genome-wide scale by 
genotyping a subset of representative SNPs known as the “tagSNPs”, which are in LD 
with many other SNPs. Most commonly in a GWAS, unrelated cases are compared to 
similar individuals without the disease (controls) to determine whether SNP genotype is 
associated with disease status. With its ability to interrogate across the entire genome in 
an agnostic fashion, GWAS studies have enriched our understanding of how germline 
variations contribute to the genetic susceptibility of complex diseases, such as cancer 
(Stadler et al., 2010).  
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In terms of HNSCC risk, some evidence from GWAS have emerged, pointing 
towards significant germline variants within alcohol dehydrogenase genes (rs1573496-
ADH7, rs1229984-ADH1B, rs698-ADH1C) as well as near aldehyde dehydrogenase 2 
gene (rs4767364) and DNA repair genes HELQ and FAM175A (rs1494961) (McKay et 
al., 2011). However, published GWAS studies have been limited by the inclusion of non-
HNSCC cases (esophageal cancer) or have focused on only one anatomical sub-site with 
a very limited sample size (Bhatnagar, Dabholkar, & Saranath, 2012; McKay et al., 
2011). As well, the majority of known variants have been examined in the context of 
HNSCC risk only.  
2.3 Germline Variations and HNSCC Survival 
 
A genome-wide approach has not been utilized to examine germline variations in 
the context of HNSCC prognosis. Although evidence from candidate gene studies has 
linked polymorphisms in DNA repair, xenobiotic metabolism, cell cycle, and growth 
factor pathways to survival outcomes in HNSCC, overall there is a paucity of evidence 
linking genetic variants to HNSCC outcomes, thereby limiting their clinical utility 
(Hopkins et al., 2008) To date, some associations with HNSCC survival outcomes have 
been observed with polymorphisms in XRCC1, FGFR4, and CCND1, genes that function 
in DNA repair, cell growth, and cell cycle control, respectively. While FGFR4 and 
CCND1 polymorphisms have been linked to poor prognosis across several studies, 
XRCC1 and ERCC2 polymorphisms have been associated with improved survival (Azad 
et al., 2012; da Costa Andrade et al., 2007; Gal, Huang, Chen, Hayes, & Schwartz, 2005; 
Matthias et al., 1998; Monteiro, Varzim, Pires, Teixeira, & Lopes, 2004; Quintela-
Fandino et al., 2006; Streit et al., 2004) (Figure 1). Despite these reported associations, 
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the studies have generally been limited by several important factors. These include: 1) 
heterogeneity in study populations, 2) small sample sizes, 3) incomplete documentation 
of cohort characteristics and outcomes, 4) lack of adequate adjustment for confounders, 
5) inadequate correction for multiple-comparisons, and/or 5) non-replication of results. 
(Hopkins et al., 2008). 
Figure 1. Summary of germline variations associated with HNSCC  
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*Abbreviations: OS, overall survival; DFS, disease-free survival; AHR, adjusted hazard ratio; 
LR, log-rank test 
1Matthias et al., 1998 
2Monteiro, Varzim, Pires, Teixeira, & Lopes, 2004 
3da Costa Andrade et al., 2007 
4Streit et al., 20045.Gal, Huang, Chen, Hayes, & Schwartz, 2005 
6Quintela-Fandino et al., 2006 
7Azad et al., 2012 
3. Study Objective 
In order to gain a better understanding of whether germline variations influence 
HNSCC survival outcomes, we performed a large-scale GWAS in a well-defined 
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prospectively recruited cohort of HNSCC patients. The main objective of this study was 
to identify germline variants associated with survival in patients with HNSCC. 
Specifically, the aim was to identify common polymorphisms associated with overall 
survival in patients with primary squamous cell carcinoma of the oral cavity, oropharynx, 
and hypopharynx. 
4. Methods 
4.1. Study Enrollment and Databases 
Patients with HNSCC diagnosed and treated at the Princess Margaret Cancer 
Centre in Toronto, Ontario, Canada at the Wharton Head & Neck Centre have been 
prospectively accrued for an institutional translational study on head and neck cancers 
since January 2007. The Princess Margaret Cancer Centre is the largest comprehensive 
cancer centre in Canada, where cancer care is centralized to regional cancer centres with 
capacity for multidisciplinary care. The Wharton Head & Neck Centre provides care for 
approximately 800 new patients with head and neck cancer each year. 
After histopathologic confirmation of a diagnosis of head and neck cancer, 
patients were approached to participate in the study during their initial clinic visits. 
Informed consent for study participation was obtained prior to study enrollment by a 
study coordinator. All recruited study subjects were 18 years of age or older. Whole 
blood samples were obtained prior to treatment initiation. A self-administered 
questionnaire was provided at the time of enrollment to collect demographic and risk 
factor information including gender, ethnicity, and smoking habits. Additional clinical 
information including TNM stage, pathology, HPV status, treatment data, outcome data, 
and duration of follow-up were prospectively collected and stored in the Head and Neck 
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Anthology of Outcomes Systems-a institutionally developed point-of-care physician-
collected electronic data storage system (Wong et al., 2010). HPV status was determined 
via staining for p16 protein expression in primary tumor tissues using 
immunohistochemistry. Positive p16 staining is indicative of HPV positive disease. 
Patients were staged using the American Joint Committee on Cancer TNM classification 
7th edition by one or more members of an interdisciplinary team of head and neck 
surgeons, radiation oncologists, and medical oncologists. Patients treated with primary 
surgery were staged according to pathological TNM stage of the resected specimen. 
Those treated with primary radiotherapy were clinically staged based on pre-treatment 
examination and imaging. Collected survival outcomes were verified using the Ontario 
Cancer Registry and patients’ electronic medical records. 
4.2. Ethics Approval 
Institutional Ethics approval was obtained from the University Health Network 
Research Ethics Board for the collection of patient information (clinical and 
questionnaire) and blood samples as well as subsequent analyses (REB: 07-0521-CE).   
4.3. Study Population 
For the purpose of this study, patients with histopathologically confirmed primary 
invasive squamous cell carcinoma of the oral cavity, oropharynx, and hypopharynx were 
included. Exclusion criteria included refusal of blood collection, non-squamous cell 
carcinoma pathology, or synchronous cancers.  For survival analyses, patients with 
distant metastases at presentation, palliative treatment intent, treatment at another 
 11 
institution, and/or had less than two years of follow-up after the date of diagnosis were 
excluded.  
4.4 Data Collection 
 4.4.1. Demographic and Clinical Information 
Demographic information including age, gender, self-reported ethnicity, and 
smoking status were retrieved from the questionnaire database. TNM stage, HPV status, 
treatment modality, and outcome data were retrieved from the Head and Neck Anthology 
of Outcomes Systems.  
4.4.2. Blood Collection and DNA Extraction 
 Blood samples were collected from patients in clinic using 
Ethylenediaminetetraacetic acid (EDTA) vacutainers. The samples were processed within 
2 hours of blood collection (centrifugation at 4 degrees Celsius for 30 minutes at 2000g) 
at the Princess Margaret Cancer Centre. The plasma and serum of each sample were 
transferred to cryovials and stored separately. The remaining cellular component at the 
bottom of the EDTA tubes were aliquoted to cryovials and stored as whole blood at -80 
degrees Celsius for up to two years. Prior to genotyping experiments, whole blood 
samples were thawed at room temperature for 1-2 hours. DNA was then extracted from 
whole blood samples using 5Primer ArchivePure DNA Blood Kit (Cat# 2300740) 
according to manufacturers’ instructions. DNA concentration and purity were measured 
using the Nanodrop Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 
Samples that met minimal requirements of 50-100 ng/µl and total DNA amount of 1-2 µg 
were plated on to 96-well plates and sent for genotyping. 
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4.5 Genotyping  
Genotyping was performed using a custom-designed Illumina OncoArray 
BeadChip at the Center for Inherited Disease Research (CIDR) along with 13 other 
HNSCC studies that were a part of the International Head and Neck Cancer 
Epidemiology Consortium (INHANCE)/Genetic Associations and Mechanisms in 
Oncology (GAME-ON) Consortium. Briefly, the custom OncoArray included a genome-
wide backbone of approximately 270,000 tagSNPs as well as over 250,000 additional 
custom SNPs. Ancestry Informative Markers (AIMs) were included on the array. Custom 
SNPs selected included those involved in candidate pathways including alcohol 
metabolism, DNA repair, nicotine addition, as well as genetic variants known to be of 
importance in lung squamous cell carcinoma, which share similar risk factors as HNSCC. 
Candidate variants identified through previous HNSCC GWAS, imputation analyses, and 
TCGA studies of HNSCC and lung squamous cell carcinoma were also included. 
HapMap DNA were plated at CIDR in unique positions on each DNA plate and ran with 
study samples.  
4.6 Quality Control 
Rigorous quality control (QC) procedures are necessary in GWAS to minimize 
bias and increase the probability of identifying a true association (Laurie, Doheny, & 
Mirel, 2010). Prior to the release of genotypes, several technical filters were applied by 
the genotyping centre at CIDR. These include excluding SNPs with HapMap replicate 
errors, samples with high duplicate errors, and samples with contaminated DNA. 
Genotyping calls were further reviewed and cleaned by an independent group within 
INHANCE with expertise in GWAS genotype calling and quality control. A systematic 
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pipeline of quality control procedures was then conducted on the OncoArray genotype 
data. The quality control procedures were implemented in PLINK version 1.09 and R 
studio Version 0.98.1103. Principal Components Analysis (PCA) was performed using 
EIGENSOFT version 6.0.1. Both sample-based and marker-based quality control were 
performed as follows: 
4.6.1 Gender Check 
Sex inconsistencies were identified by comparing the reported sex of individuals 
against their predicted sex as determined by their X chromosome heterozygosity rate 
calculated in PLINK. Individuals with sex chromosome abnormalities were identified. If 
the identified sex chromosome abnormality had no known influence on HNSCC 
prognosis, the individuals were not excluded from downstream analyses. Individuals with 
unresolved sex-discrepancies were excluded.  
4.6.2 Relatedness  
Cryptic relatedness can increase the type 1 error rate. Pairwise familial 
relationships were estimated using a method of moments procedure implemented in 
PLINK.  Identify-by-descent (IBD) coefficients (Z0, Z1, and Z2), representing the 
probability of sharing 0, 1, or 2 alleles identical by descent, were estimated. The 
probability of sharing 0 (Z0) alleles IBD was then plotted against the probability of 
sharing 1 allele (Z1) IBD for each pair. One individual from each pair with proportion 
IBD greater than 0.120 (more closely related than first cousins) was excluded.  
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4.6.3 Genotype call rates by individual and SNP 
Sample call rate refers to the proportion of SNPs that were successfully genotyped 
per sample. Samples where a significant proportion of SNPs failed genotyping may 
contain poor quality DNA that can give rise to erroneous genotype calls. Samples with 
call rates less than 98% were excluded. Similarly, marker call rate, which is the 
proportion of samples with a successful genotype call for each marker, was assessed as 
an indicator of marker quality. SNPs with call rates below 98% were excluded. 
 4.6.4 Minor Allele Frequency 
Distribution of minor allele frequency (MAF) across SNPs were examined. To 
ensure adequate power and minimize false positives, SNPs with MAF <0.05 were 
excluded from survival analyses.  
 4.6.5 Batch Effects 
Genotyping for the study was completed across a total of thirteen 96-well plates. 
As such, each plate was examined and compared in terms of sample call rate and MAF to 
assess for potential differences by plate.   
 4.6.6 Population Substructure 
The presence of population stratification is a major source of confounding in 
GWAS. False results may be observed due to differences in ancestry rather than true 
association between genotype and outcome of interest. Principal components analysis 
(PCAs) using a panel of 1847 ancestry informative markers was used to assess for 
population stratification. Study genotype data was first examined alone. Study genotypes 
were then merged with HapMap phase 3 data in order to further define population 
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identities. Population outliers (exceeding 6 standard deviations) as identified along the 
top 10 principal components using EIGENSOFT were excluded from further analyses.  
4.6.7 Heterozygosity 
Heterozygosity rates that significantly deviate from the average may be indicative 
of possible sample contamination, inbreeding, and/or poor data quality. Heterozygosity 
rate was estimated using PLINK, which computed the observed and expected autosomal 
homozygous genotype counts for each sample. To obtain the heterozygosity rate, the 
number of observed number of homozygotes was subtracted from the number of non-
missing autosomal genotypes and divided by the number of non-missing autosomal 
genotypes. The heterozygosity rate was then plotted for each sample to identify outliers 
that were more than 6 standard deviations away from the mean.  
 4.6.8 Hardy-Weinberg Equilibrium 
Checking whether each marker was in Hardy-Weinberg Equilibrium (HWE) was 
the final step in the quality control procedures. Under Hardy-Weinberg assumptions, 
allele and genotype frequencies in a population remain constant from one generation to 
the next. SNPs with significant deviations from HWE may be suggestive of genotyping 
errors. However, deviations from HWE can also be observed when a true association is 
present. As such, the HWE p value cutoff was set to 10-6 in this study. 
4.7 Statistical Analysis 
The outcome of interest was overall survival, which was defined as the time 
interval between the date of diagnosis and the date of death from any cause. Duration of 
follow-up was calculated from the date of diagnosis until date of last known follow-up or 
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contact. Patients known to be alive were censored at the time of last contact, up to 
February 28, 2015. Cox proportional hazards models were used to assess the association 
between SNPs and overall survival. Autosomal SNPs that met quality control criteria 
were included in the genome-wide analysis. Multivariate models adjusting for known 
clinical confounders were utilized. Multicollinearity of variables was assessed using 
variance inflation factor. The proportional hazards assumption was assessed for included 
variables. Heteroscedasticity-consistent standard errors were used in the Cox multivariate 
models.  Three genetic models of inheritance (additive, dominant, and recessive) were 
assessed and the model of best fit was selected for analyses. Top SNPs meeting the 
threshold for “suggestive” association (p value <10-5) were further investigated. Kaplan-
Meier survival estimates were plotted and the log rank test was used to compare survival 
times across different genotypes. Regional coverage around significant SNPs and LD 
between SNPs were assessed using LocusZoom version 1.1. Exploratory subgroup 
analyses based on anatomical sub-site were conducted.  
5. Results 
5.1 Quality Control 
 Detailed results of quality control procedures are shown in the supplementary 
information section. An overview of samples excluded during quality control procedures 
are shown in Figure 2. After completing sample-based quality control procedures, 47 
individuals were excluded. Twelve samples were excluded by CIDR due to poor 
performance. Eleven individuals were flagged during gender check. Of these, 3 were 
identified as database errors, where the gender by genotype was correct but was 
erroneously recorded as the opposite sex in the clinical database. These errors were 
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subsequently corrected and these individuals remained included in the analyses. Four 
individuals were identified as having sex chromosome abnormalities. Specifically, 3 
patients were identified as XXY and one as XX/XO. Given that these sex chromosome 
abnormalities were not known to impact HNSCC survival, these individuals remained in 
subsequent analyses. Two individuals who underwent bone marrow transplantation had 
genotyped genders matching that of their donors’. These individuals were excluded along 
with two additional individuals with unresolved gender inconsistency. Six individuals 
were excluded due to cryptic relatedness. Overall, the per sample call rates were high 
with a mean call rate of 98.7%. Twenty samples with call rates less than or equal to 98% 
were excluded. After exclusion, the mean per sample call rate was 99.9%. During 
analysis of population substructure, 4 individuals were excluded given that they were 6 
standard deviations away from the top 10 PCA means. One individual was removed due 
to an extreme heterozygosity rate.  
Figure 2. Summary of sample quality control 
Number of samples before sample quality control: 1,145 
 Reason for Exclusion Excluded 
 
 Poor performance (CIDR) 12 
 Unresolved sex inconsistency 2 
 Bone marrow transplant 2 
 Cryptic relatedness 6 
 Sample call rate <98% 20 
 Population outliers 4 
 Heterozygosity rate >6 S.D. from mean 1 
  Total=47 
Number of Samples After Sample Quality Control: 1,098 
 
In total, genotyping for 533,631 SNPs was attempted including 517,820 
autosomal SNPs, 15,258 X chromosome SNPs, 397 Y chromosome SNPs, 6 XY 
chromosome SNPs, and 150 mitochondrial SNPs. The mean per SNP call rate was 
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98.7%. A total of 19,071 SNPs not meeting the 98% call rate cut off and 748 duplicate 
SNPs were excluded. A total of 35,827 monomorphic SNPs were excluded. The 
distribution of minor allele frequencies across SNPs are shown in Figure 5 
(Supplementary Information). After exclusions, the mean per SNP call rate was 99.9% 
and the mean minor allele frequency was 0.2013. No significant batch effects were 
observed across the 13 genotyping plates. Overall, 55,646 variants were excluded after 
marker-based quality control procedures, with 477,985 variants remaining for further 
analyses. A summary of SNP-based quality control procedures is shown in Figure 3.  
Figure 3. Summary of SNP quality control 
Number of SNPs before QC: 533,631 
 Reason for Exclusion  Excluded 
 
 SNP call rate <98% 19,071 
 Duplicate SNPs 748 
 Monomorphic SNPs 35,827 
 Total=55,646 
Number of Samples After Sample QC: 477,985 
5.2 Patient Characteristics 
Between 2007-2014, 1178 patients with newly diagnosed squamous cell 
carcinoma of the oral cavity, oropharynx, and hypopharynx were recruited into the study.   
Thirty-three individuals were excluded due to ineligible anatomical sub-site or blood 
samples. After completing quality control procedures, 1098 patients remained. Prior to 
survival analysis, 172 individuals were excluded due to inadequate follow-up time (less 
than 2 years) and 42 were excluded due to treatment intent and/or treatment elsewhere. A 
total of 884 individuals were eligible for survival analyses. Their demographic and 
clinicopathologic characteristics are shown in Table 1.  See Supplementary Information 
Figure 1 for an overview of included/excluded samples. 
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Table 1. Characteristics of patients eligible for survival analysis (N=884) 
 N % 
Age at diagnosis   
Mean 61.2+/- 11.0 years  
Range 27.0-91.0 years  
Gender   
Male 669 75.7 
Female 215 24.3 
Self-Reported Ethnicity   
Caucasian 727 86.0 
South Asian 50 5.9 
East Asian 33 3.9 
Black 9 1.0 
Other 26 2.9 
NA 39 4.4 
Anatomical Sub-site   
Oral Cavity 385 43.6 
Oropharynx 451 51.0 
Hypopharynx 48 5.4 
HPV status   
Positive 316 35.7 
Negative 114 12.9 
Unknown 454 51.4 
Primary Treatment   




Vital Status   
Alive 686 77.6 
Dead 198 22.4 
Duration of follow-up   
Mean 3.1 +/-1.8 years  
Range 0.1-7.6 years  
*NA=No self-reported ethnicity information 
The majority of patients were male and self-identified Caucasian. Using principal 
components, 768 individuals of European descent were further defined based on their 
similarity to CEU and TSI HapMap populations. Other populations, namely Indian, East 
Asian, African, and Others were also identified using reference HapMap populations. The 
most common anatomical sub-site was oropharynx followed by oral cavity. 
Hypopharyngeal cancer was the diagnosis in a small proportion of patients only. Within 
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the oropharyngeal sub-site, the majority of patients had p16 positive disease attributable 
to HPV infection. Radiotherapy was more common than surgical resection as the primary 
treatment modality. The average duration of follow-up was approximately 3 years. The 
total number of deaths in the study was 198. The 1, 3, and 5-year survival rates were 
91.3%, 78.2%, and 73.3%, respectively.  On univariate analyses, age, overall TNM stage, 
anatomical sub-site, and treatment modality were significantly associated with overall 
survival. Gender was not significantly associated with survival (results not shown).  
5.3 Germline Variants Associated with HNSCC Survival 
To ensure adequate power, only SNPs with MAF equal to or greater than 0.05 
were considered for survival analyses.  None of the top SNPs had allele frequencies that 
significantly deviated from HWE. A Cox proportional hazards model adjusting for age, 
overall TNM stage, and anatomical sub-site under the additive model of genetic 
inheritance was fitted to assess the association between SNPs and overall survival. 
Treatment was highly collinear with anatomical sub-site and therefore was not included 
in the multivariate model. The primary analysis was performed within patients of 
European descent (as identified by PCA) only, given that this was the predominant ethnic 
group (87% of patients eligible for survival analyses). The Quantile-Quantile (Q-Q) plot 
did not demonstrate systemic inflation of the test statistic (λmedian=0.994) (Figure 4). The 
Manhattan plot for overall survival in European patients is shown in Figure 5. Although 
no single SNP reached the level of genome-wide significance at p<5x10-8, 3 identified 
variants were suggestive of significance (p <1x10-6). 
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Figure 4. Q-Q plot of GWAS for overall survival in European HNSCC patients. 
 
Figure 5. Manhattan plot of GWAS for overall survival in European HNSCC 
patients
 
*In Figures 4 and 5, associations expressed as –log10(p). P values were two-sided and were from 
multivariable Cox proportional hazards models adjusted for age, site, and overall TNM stage. 
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The SNPs most significantly associated with overall survival in Europeans are 
summarized in Table 2. All top SNPs were found within annotated genes. The Kaplan-
Meier plots for top SNPs are shown in Figure 6. 
Table 2. Significant SNPs associated with overall survival in European HNSCC patients 
(N=768) 
Ch Band SNP Position Gene Risk 
Allele 
MAF HR (95% CI) P-value 
6 6p12.3 rs1974051 47916225 PTCHD4 G 0.08 2.09(1.57-2.79) 4.94x10-7 
9 9p24.2 rs10812227 2548556 VLDLR-AS1 T 0.14 0.32(0.20-0.50) 8.71x10-7 
9 9p24.2 rs12237653 2551654 VLDLR-AS1 C 0.14 0.32(0.20-0.50) 9.18x10-7 
*Abbrevations: Ch, Chromosome; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval 
*SNP names based on dbSNP137 
 
Figure 6. Unadjusted Kaplan-Meier curves for overall survival by genotype 








The top-ranking SNP (rs1974051) was located within the patched domain 
containing 4 (PTCHD4) gene at the 6p12.3 locus. Each minor allele was associated with 
a hazard ratio (HR) of 2.09 (95% CI, 1.57-2.79). The other 2 top-ranking SNPs 
(rs10812227 and rs12237653), along with one additional SNP (rs4741732) that was 
trending towards significance, were found within the 9p24.2 region. These SNPs showed 
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a protective effect in terms of overall survival (HR, 0.32; 95% CI, 0.20-0.50). They were 
in high LD with one another and were clustered within the very low density lipoprotein 
receptor antisense RNA 1 gene (VLDLR-AS1) (Supplementary Information Figure 10).  
There were only 116 non-European patients and the number of patients within 
each non-European subgroup was small (63 South Asian, 27 East Asians, 9 African, and 
17 others/admixed). As such, a trans-ethnic meta-analysis was not performed. 
5.4 Sensitivity Analyses Based on Anatomical Sub-site 
Etiology and survival outcomes in HNSCC significantly vary by anatomical sub-
site. As such, exploratory subgroup analyses were conducted within the oropharynx and 
oral cavity sub-sites. The sample size of the hypopharynx subgroup was too small to 
yield reliable estimates.  
Within the oropharynx, in addition to age and TNM stage, Cox proportional 
hazard models were also adjusted for HPV status as determined by p16 positivity and 
smoking status. An intergenic variant (rs7862541) located within the 9p24.1 region met 
the genome-wide significance threshold (p=2.44x10-8).  Six additional variants were 
suggestive of significance as shown in Table 3.  
Table 3. Significant SNPs in the oropharynx sub-site in European HNSCC patients 
(N=376) 
Ch Band SNP Position Gene Risk 
Allele 
MAF HR (95% CI) P-value 
9 9p24.1 rs7862541 5604769 intergenic T 0.10 2.98(2.03-4.38) 2.44x10-8 
4 4q32.2 rs75965042 164037795 NAF1 C 0.06 3.82(2.34-6.23) 7.43X10-8 
4 4q32.2 rs17574945 164056625 NAF1 T 0.06 3.82(2.34-6.23) 7.43X10-8 
1 1p34.1 rs6667593 45131401 TMEM53 C 0.06 2.65(1.83-3.82) 2.29x10-7 
1 1q21.3 rs7523883 153214867 intergenic C 0.34 2.24(1.64-3.05) 3.93x10-7 
4 4q32.3 rs62335075 164155332 intergenic T 0.20 2.41(1.70-3.41) 6.85x10-7 
17 17q21.2 rs72829884 46681084 HOXB6 C 0.07 3.36(2.08-5.43) 7.62x10-7 
*Abbrevations: Ch, Chromosome; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval 
*SNP names based on dbSNP137 
*Cox-proportional hazard model adjusted for age, stage, p16 status, and smoking status 
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Within the oral cavity subgroup, the top variant reaching genome-wide 
significance was an intergenic variant located upstream of the patched 1 (PTCH1) gene 
(p=2.27x10-10). Three additional SNPs achieved suggestive significance (Table 4).  
Table 4. Significant SNPs in the oral cavity sub-site in European HNSCC patients 
(N=304) 
Ch Band SNP Position Gene Risk 
Allele 
MAF HR (95% CI) P-value 
9 9q22.3 rs55957307 98337392 intergenic C 0.07 3.86(2.54-5.85) 2.27x10-10 
2 2q32.3 rs79913292 192698793 intergenic G 0.05 3.31(2.08-5.29) 5.05x10-7 
10 10q21.2 rs73255291 61849599 ANK3 A 0.06 2.86(1.89-4.32) 5.94x10-7 
6 6q12.3 rs1974051 47916225 PTCHD4 G 0.08 2.74(1.83-4.09) 8.55x10-7 
*Abbrevations: Ch, Chromosome; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval 
*SNP names based on dbSNP137 
*Cox-proportional hazard model adjusted for age, stage 
6. Discussion 
6.1 Germline Variations and Cancer Survival 
While it has been established that germline variations are associated with complex 
disease risk, a growing body of evidence suggests that they may also be important in 
improving our understanding of as well as our ability to predict disease outcomes. In 
cancer, germline variations may impact disease progression and prognosis by affecting 
hosts’ response to treatment as well as by influencing tumors’ somatic and epigenetic 
landscapes (Coate et al., 2010; Dworkin et al., 2010; Pujana, 2014). Utilizing candidate 
gene and genome-wide approaches, germline variants have been associated with 
treatment response and/or resistance, relapse and metastasis susceptibility, as well as 
survival time in a variety of solid tumors and hematologic malignancies. Specifically, 
GWAS has been utilized to assess germline variations’ association with survival 
outcomes in lung, breast, ovarian, pancreatic, colorectal cancers, and acute lymphoblastic 
leukemia (Braun et al., 2013; Han et al., 2014; Hu et al., 2012; Innocenti et al., 2012; 
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Rafiq et al., 2013; Shu et al., 2012; Tang et al., 2015; C. Wu et al., 2014; X. Wu et al., 
2013; L. Xu et al., 2012; W. Xu et al., 2015; Yang et al., 2012).  
To our knowledge, this is the first study to utilize a genome-wide approach to 
investigate germline variants’ association with survival outcomes in HNSCC. Out of over 
530,000 SNPs examined, although no SNPs reached the genome-wide significance 
threshold of 5x10-8, we identified three common germline variants that may influence 
survival outcomes in HNSCC patients.  
6.2 Germline Variants Associated with HNSCC Survival 
The most statistically significant SNP (rs1974051) from the Europeans only all 
sub-sites analysis was located within an intronic region of the PTCHD4 gene. The allele 
G, present in approximately 8% of European patients, was associated with a two-fold 
decrease in overall survival. PTCHD4, also known as PTCH53, is a homolog of PTCH1-
the receptor for Sonic Hedgehog (SHH). Although the exact function of PTCHD4 has not 
been well characterized, recent evidence suggests that it may function similarly to other 
patched family proteins and act as a suppressor of Hedgehog signaling (Chung, Larsen, 
Chen, & Bunz, 2014). 
The Hedgehog pathway regulates key human development processes including 
cellular differentiation and proliferation. Inappropriate activation of this pathway has 
been linked to tumorigenesis in a variety of human cancers (Harris, Samant, & Shevde, 
2011; Rubin & de Sauvage, 2006). In HNSCC, overexpression of hedgehog pathway 
components have been observed (Dimitrova et al., 2013). It has been suggested that 
aberrant hedgehog signaling may play an important role in the pathogenesis of HPV 
negative tumors (Fertig et al., 2013; Gan et al., 2014). Our sensitivity analysis by 
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anatomical sub-site’s finding of a significant variant near the PTCH1 gene within the oral 
cavity, a predominantly HPV-negative sub-site, was in keeping with this hypothesis. In 
addition, Hedgehog activation has been associated with resistance to radiotherapy, 
epithelial to mesenchymal transition, and rapid tumor repopulation following treatment 
(Gan et al., 2014; Ma et al., 2013; Ohta et al., 2009; Sims-Mourtada et al., 2006). It was 
previously found in the landmark RTOG 90-03 trial that individuals with high expression 
of GLI1, a downstream target of Hedgehog activation, had decreased overall survival, 
poor local control, and high rates of distant metastases (Chung et al., 2011). Inhibition of 
the Hedgehog pathway by targeted agents has also shown promise in enhancing the 
antitumor effects of chemoradiation (Gan et al., 2014; Mozet, Stoehr, Dimitrova, Dietz, 
& Wichmann, 2013). Further studies are required to elucidate the function of PTCHD4 
and PTCH1 in the context of HNSCC and to uncover the mechanisms through which 
germline variations in the Hedgehog pathway may result in differences in HNSCC 
progression and outcomes. This study contributes to the growing body of literature from 
in vitro, in vivo, and epidemiologic studies demonstrating the importance of the 
Hedgehog pathway as a potential oncogenic driver and therapeutic target in HNSCC.  
In the overall analysis, the other two variants (rs10812227 and rs12237653) 
suggestive of a significant association were also intronic variants. They were in high LD 
with one another and were both situated within VLDLR-AS1. In European patients, these 
variants were relatively common with a MAF of 0.14 for both. The variants were located 
within a chromosomal region that has long been linked to HNSCC. Loss of 
heterozygosity within the 9p21-24 region is one of the most frequently observed 
chromosomal alterations in HNSCC, which has been associated with poor prognosis 
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(Coon et al., 2004; Gollin, 2001; Rybicki, 2003). In addition to the well-known CDKN2A 
gene located at 9p21 encoding for the p16 protein, the region has also been suspected to 
harbor additional HNSCC tumor suppressor genes (Beder et al., 2003; Gunduz et al., 
2009). The SMARCA2 gene, located approximately 350kb downstream from rs10812227 
and rs12237653, is one of such putative tumor suppressors that has been examined by our 
group and others (Gunduz et al., 2009; Wang et al., 2013).  
VLDLR-AS1, located at 9p24.2, is a non-protein coding gene that encodes for a 
long non-coding RNA (lncRNA). The RNA is transcribed in the antisense direction 
relative to the protein-coding VLDLR gene, however its exact function remains unknown. 
While non-protein coding DNA was once considered genomic “junk” with no functional 
significance, it has become increasingly apparent in recent years that they serve important 
regulatory functions (Amaral, Dinger, Mercer, & Mattick, 2008; Cheetham, Gruhl, 
Mattick, & Dinger, 2013; Dunham et al., 2012; Kapranov, Willingham, & Gingeras, 
2007). In particular, lncRNAs, which are noncoding RNAs of greater than 200bp in 
length, have been shown to play integral roles in cancer development and progression. 
LncRNAs can be found in intergenic regions, within introns of protein-coding genes, or 
in sense or antisense orientation to protein-coding genes (Cheetham et al., 2013; Mercer, 
Dinger, & Mattick, 2009). Antisense non-coding RNAs, such as VLDLR-AS1, are a type 
of lncRNA that can regulate the expression of their neighboring genes in cis or affect 
more distant loci in trans (Villegas & Zaphiropoulos, 2015). Although some studies have 
linked alterations in VLDLR to cancer including the presence of VLDLR somatic 
mutations in 6% of HNSCCs in TCGA as well as an association between overexpression 
of a VLDLR splice variant and cancer metastasis, the level of evidence remains low 
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overall (Cerami et al., 2012; He et al., 2010; He, Lu, & Guo, 2013). Given that antisense 
RNA can modulate chromatin structure and recruit epigenetic effectors to specific 
genomic loci, it is possible that the candidate germline variants in VLDLR-AS1 may 
functionally impact neighboring gene(s) with known significance in HNSCC, such as 
SMARCA2 (Mercer & Mattick, 2013). Alternatively, it is also possible that the identified 
polymorphisms in VLDLR-AS1 do not have functional significance but served as markers 
for casual variant(s) in LD at another nearby gene that directly impact HNSCC survival.  
6.3 Limitations 
This study identified novel germline variants that may impact survival outcomes 
in HNSCC patients. However, there were several limitations. Despite having a 
moderately large sample size of HNSCC patients, a reason for the lack of associations 
reaching genome-wide significance may still be limited power. In general, there is a 
paucity of prospectively recruited cancer cohorts with large sample sizes and 
comprehensive demographic and survival information, thereby limiting the progress of 
GWAS on cancer survival. As such, the formation of collaborative consortia amongst 
multiple institutions is key to accruing large enough sample sizes to achieve adequate 
power. The next stage of this study will involve a combined analysis of additional 
HNSCC cohorts in the INHANCE consortium recruited from various centers within the 
United States and Europe. The presence of heterogeneity in terms of anatomical sub-sites 
also contributed to the limited power. Our sensitivity analyses suggested that different 
anatomical sub-sites of HNSCC may be characterized by distinct germline genetic 
profiles. Further studies based on single sub-site and/or HPV positivity will likely 
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improve our ability to detect robust associations with survival outcomes compared to 
studies that include all HNSCC patients.  
Validations of our findings in other independent HNSCC cohorts with European 
patients is needed.   Examination of non-European cohorts and follow-up functional 
studies are also needed. Similar to our study, the majority of GWAS hits to date lie within 
intergenic or intronic regions (Hindorff et al, 2015). It has been hypothesized that these 
types of variants indirectly influence gene regulation instead of directly disrupt protein 
products (Edwards, Beesley, French, & Dunning, 2013). In order to examine the top 
candidate variants’ functional significance, we plan to perform fine mapping of the 
identified loci via imputation analyses, in-silico analyses, and expression studies (i.e. 
luciferase reporter assays, gain/loss of function studies). Future direction also includes 
pathway-based analyses, examination of cancer-specific survival, and trans-ethnic 
analyses. 
7. Conclusions 
Employing a genome-wide approach, we found preliminary evidence suggesting 
that germline variations may influence prognosis in patients with primary HNSCC. 
However, further studies are required to validate these findings and to uncover the 
mechanisms underlying their functional significance. With its ease of detection, germline 
variants can be used as valuable biomarkers to guide prognostication and treatment 
selection in the clinical setting. Since multi-modality treatment of HNSCC often results 
in significant morbidity, treatment de-escalation in patients with favorable disease 
features is an area of ongoing research. Findings from our study, particularly the 
discovery of protective variants rs10812227 and rs12237653, may help to identify such a 
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subgroup of patients. In order to ultimately realize personal cancer medicine in HNSCC, 
it is likely that the integration of germline, somatic, histopathological, and clinical data 
will be required.  
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Figure 5. Distribution of minor allele frequencies before and after SNP and sample-based 
QC 
a) Before QC 
 





Figure 6. First two principal components of the study population with and without 





*1837 Ancestral Informative Markers (AIMS) included on the custom OncoArray were 
used to generate principal components. Population outliers were excluded. 
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Figure 7. First two principal components of the study population Europeans with and 




*1837 Ancestral Informative Markers (AIMS) included on the custom OncoArray were 





Figure 8: Heterozygosity rate vs. proportion of missing SNPs per sample after SNP and 
sample-based QC 
 
*one sample was excluded based on heterozygosity rate greater than 6 standard 
deviations from the mean 
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Figure 10. Regional plots for top snps across all anatomical sub-sites 
a) rs1974051 
 
b) rs10812227 and rs12237653 
 
*rs10812227 and rs12237653 are in high LD with r2>0.8. FLJ35024 is also known as 
VLDLR-AS1.  
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Figure 11. Regional plot for the most significant SNP in oropharynx sub-site 
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